Karyopharm Announces Investor and Analyst Event at the American Society of Hematology 2020 Annual Meeting

Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is set to host a virtual investor and analyst event on December 8, 2020, from 1:00 - 2:30 p.m. ET. The event will focus on the Company’s cancer therapy pipeline and key data from the American Society of Hematology (ASH) 2020 Annual Meeting. Karyopharm's management, alongside experts in multiple myeloma and leukemia, will present and engage in a Q&A session. The event will be accessible via phone and an audio webcast will be available on their investor website after the event.

Positive

• Karyopharm Therapeutics is hosting a virtual event to discuss its clinical pipeline.
• Participation of recognized experts in the field may enhance credibility and investor interest.
• The recent approvals for XPOVIO highlight Karyopharm's innovative approach to cancer therapies.

Negative

• None.

NEWTON, Mass., Dec. 1, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will host a virtual investor and analyst event to discuss the Company's pipeline of clinical programs and highlights from the data presentations being given at the American Society of Hematology (ASH) 2020 Annual Meeting. This Karyopharm-sponsored event is scheduled for Tuesday, December 8, 2020 from 1:00 - 2:30 p.m. ET.

The Karyopharm management team will be joined by a group of recognized multiple myeloma, diffuse large B-cell Lymphoma and leukemia experts to provide additional external context and participate in the Q&A portion of the call.

To access the event, please dial (877) 870-4263 (local) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call.  A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com. 

View original content:http://www.prnewswire.com/news-releases/karyopharm-announces-investor-and-analyst-event-at-the-american-society-of-hematology-2020-annual-meeting-301183034.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When is Karyopharm's investor and analyst event scheduled?

Karyopharm's investor and analyst event is scheduled for December 8, 2020, from 1:00 to 2:30 p.m. ET.

What topics will be discussed at Karyopharm's event?

The event will focus on Karyopharm's pipeline of clinical programs and highlights from the ASH 2020 Annual Meeting.

Who will participate in Karyopharm's investor event?

Karyopharm's management team and recognized experts in multiple myeloma, lymphoma, and leukemia will participate.

How can I access the Karyopharm investor event?

The event can be accessed by dialing the provided phone numbers or through a live audio webcast available on Karyopharm's investor website.

What achievements has Karyopharm made regarding XPOVIO?

Karyopharm's lead compound, XPOVIO, received FDA accelerated approval in July 2019 and was approved for treating relapsed or refractory diffuse large B-cell lymphoma in June 2020.